Pablo G. Legorreta
CIK: 0001507678
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (18 total)
- Aug 7, 2026RPRX
Royalty Pharma plc
Gift(G)DirectLP interests in RPI US Partners 2019, LP
30K shares- - Aug 5, 2026RPRX
Royalty Pharma plc
Award(A)Direct65.2K shares- - May 28, 2026PROK
PROKIDNEY CORP.
Award(A)DirectDirector stock option (right to buy)
135K shares- - May 6, 2026RPRX
Royalty Pharma plc
Award(A)Direct143.8K shares- - Feb 11, 2026RPRX
Royalty Pharma plc
Award(A)Direct157.8K shares- - Nov 5, 2025RPRX
Royalty Pharma plc
Award(A)Direct36.6K shares- - Aug 8, 2025RPRX
Royalty Pharma plc
Gift(G)DirectLP interests in RPI US Partners 2019, LP
60K shares- - Aug 6, 2025RPRX
Royalty Pharma plc
Award(A)Direct21.9K shares- - Jun 3, 2025PROK
PROKIDNEY CORP.
Other(J)Indirect3.8M shares- - Jun 3, 2025PROK
PROKIDNEY CORP.
Conversion(C)Indirect3.8M shares- - May 29, 2025PROK
PROKIDNEY CORP.
Award(A)DirectDirector stock option (right to buy)
125.9K shares- - May 16, 2025RPRX
Royalty Pharma plc
Other(J)Direct530.3K shares- - May 16, 2025RPRX
Royalty Pharma plc
Award(A)IndirectClass E Ordinary Shares
13.4M shares- - May 12, 2025RPRX
Royalty Pharma plc
Gift(G)IndirectClass B Ordinary Shares
867.2K shares- - May 12, 2025RPRX
Royalty Pharma plc
Gift(G)DirectClass B Ordinary Shares
867.2K shares- - May 8, 2025RPRX
Royalty Pharma plc
Award(A)Direct288.4K shares- - Feb 4, 2025PROK
PROKIDNEY CORP.
Other(J)Indirect532.5K shares- - Feb 4, 2025PROK
PROKIDNEY CORP.
Conversion(C)Indirect532.5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 7, 2026 |  RPRX Royalty Pharma plc | Gift(G) LP interests in RPI US Partners 2019, LP | 30,000 | - | - | Direct |
| Aug 5, 2026 | RPRX Royalty Pharma plc | Award(A) | 65,216 | - | $0 | Direct |
| May 28, 2026 |  PROK PROKIDNEY CORP. | Award(A) Director stock option (right to buy) | 135,000 | - | - | Direct |
| May 6, 2026 | RPRX Royalty Pharma plc | Award(A) | 143,821 | - | $0 | Direct |
| Feb 11, 2026 | RPRX Royalty Pharma plc | Award(A) | 157,828 | - | $0 | Direct |
| Nov 5, 2025 | RPRX Royalty Pharma plc | Award(A) | 36,559 | - | - | Direct |
| Aug 8, 2025 | RPRX Royalty Pharma plc | Gift(G) LP interests in RPI US Partners 2019, LP | 60,000 | - | - | Direct |
| Aug 6, 2025 | RPRX Royalty Pharma plc | Award(A) | 21,901 | - | - | Direct |
| Jun 3, 2025 | PROK PROKIDNEY CORP. | Other(J) | 3,823,996 | - | - | Indirect |
| Jun 3, 2025 | PROK PROKIDNEY CORP. | Conversion(C) | 3,823,996 | - | - | Indirect |
| May 29, 2025 | PROK PROKIDNEY CORP. | Award(A) Director stock option (right to buy) | 125,862 | - | - | Direct |
| May 16, 2025 | RPRX Royalty Pharma plc | Other(J) | 530,348 | - | - | Direct |
| May 16, 2025 | RPRX Royalty Pharma plc | Award(A) Class E Ordinary Shares | 13,356,742 | - | - | Indirect |
| May 12, 2025 | RPRX Royalty Pharma plc | Gift(G) Class B Ordinary Shares | 867,180 | - | - | Indirect |
| May 12, 2025 | RPRX Royalty Pharma plc | Gift(G) Class B Ordinary Shares | 867,180 | - | - | Direct |
| May 8, 2025 | RPRX Royalty Pharma plc | Award(A) | 288,352 | - | - | Direct |
| Feb 4, 2025 | PROK PROKIDNEY CORP. | Other(J) | 532,535 | - | - | Indirect |
| Feb 4, 2025 | PROK PROKIDNEY CORP. | Conversion(C) | 532,535 | - | - | Indirect |
1-18 of 18 transactions
About Legorreta Pablo G.
Legorreta Pablo G. (SEC CIK 0001507678) files insider reports with the SEC as CEO, Chairman of the Board of Royalty Pharma plc (RPRX) and Director of PROKIDNEY CORP. (PROK).
Signal8 holds 12 ownership filings by Legorreta Pablo G., all Form 4s, filed between Feb 6, 2025 and Aug 7, 2026. Those filings report 18 transactions, from Feb 4, 2025 to Aug 7, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Legorreta Pablo G.'s filings is in NEW YORK, NY.
Recent filings by Legorreta Pablo G.
- Aug 7, 2026: Gift of RPRX derivative securities (Form 4, code G).
- Aug 5, 2026: Grant or award of RPRX shares (Form 4, code A).
- May 28, 2026: Grant or award of PROK derivative securities (Form 4, code A).
- May 6, 2026: Grant or award of RPRX shares (Form 4, code A).
- Feb 11, 2026: Grant or award of RPRX shares (Form 4, code A).
Other insiders filing for Royalty Pharma plc (RPRX)
- Urist Marshall, EVP, Research & Investments
- Bassler Bonnie L, Director
- Hite Christopher, EVP & Chairman, Partnering
- Coyne Terrance P., EVP & CFO
- WEATHERMAN ELIZABETH H, Director
- Norden Gregory, Director